Skip to main content
. 2018 Aug 30;12:2665–2675. doi: 10.2147/DDDT.S101145

Figure 2.

Figure 2

Anti-cataplectic effect of pitolisant expressed as cataplexy reduction (%) in the main clinical trials.

Notes: Harmony Ibis only did not show cataplexy reduction. In this study, the maximum pitolisant dose was limited to 18 mg/day (reached by 75% of patients). In addition, an important imbalance between the study sites of Harmony Ibis led to comparison of results with or without cluster grouping of sites. Cataplexy rates in Harmony Ibis were also not consistent with those seen in Harmony I.32 Harmony III study reported 76% reduction in total cataplexy and 64% reduction in partial cataplexy.46 *p<0.05 statistically significant.

Abbreviation: PL, placebo.